Sterling and Wilson Scales New Heights; Gets Awarded the World’s Largest Solar PV Plant
Sterling and Wilson, one of the dominant global forces in the solar-PV space, has bagged Turnkey Engineering Procurement and Construction along with Operation & Maintenance contract for the world’s largest single location solar PV plant in Sweihan, Emirates of Abu Dhabi. The project will deliver a capacity of 1177 MWp, easily surpassing the current largest 850 MWp single location plant in China.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170619006072/en/
Image for representation purpose only. (Photo: Business Wire)
With construction already underway, the prodigious plant, which is spread over a desert area of 7.8 sq. km, is scheduled to be fully integrated with the grid in a record timeline of just 23 months. To top it all, the project was awarded at the lowest ever recorded bid in the history of PV solar.
The plant is jointly developed by Marubeni, a Japanese integrated trading and investment giant, along with Jinko, a global leader in the solar industry, and Abu Dhabi Water and Electricity Authority (ADWEA). The consortium has successfully bid a tariff of USD 2.42 cents per kilowatt hour, marking the lowest cost ever for solar power. This is a positive demonstration of the promising future of clean energy, reducing the dominance of fossil-fuel-backed power plants.
The prestigious project will play a major role in the Emirates of Abu Dhabi achieving its aim of sustainability and energy diversification, through the use of clean energy/low carbon growth in accordance with the world’s vision of long-term environmental stewardship.
The plant, once commissioned, would save around 7 million tonnes of carbon emissions every year, a number that would be a national landmark. To put it in perspective, 1177 MWp can power around 195,000 homes, thus contributing to the welfare of the current as well as the future generations of the people of the UAE.
“We are fully geared and very excited to be a part of this important milestone in the global solar market,” said Bikesh Ogra, President – Renewable Energy, Sterling and Wilson.
Owing to the favorable government policies, India is now the 3rd largest market for solar in the world, allowing Sterling and Wilson the opportunity to become the leading solar EPC in the country. The company has created a global brand and has now grown to be the world’s largest solar EPC player outside USA and China.
Laying emphasis on the need to be competitive, he further added, “The strongest contributor to this tariff is the capital expense driven by lower equipment cost and a highly efficient system design. Our unique design offerings and state-of-the-art robotics optimizes the yield and performance of the plant.”
Sterling and Wilson also has to its credit >1400 MW of best performing solar power plants in various geographies with a powerhouse of more than 3000 qualified engineers, project managers and designers.
As the acceleration of growth in the energy sector has increased worldwide, Sterling and Wilson has ventured into the wind and energy storage sectors, covering the entire canvas in the renewable sector. Backed by its robust resources in project management, project implementation and project engineering, with projects completed in the Philippines and South Africa, and a number of projects in Zambia, Niger and Morocco under construction, the company is fully geared to deliver more than 3000 MW every year.
About Sterling and Wilson
Sterling and Wilson is an excellent example of how the Shapoorji Pallonji family has nurtured long term associations with its business partners. The Mistry and Daruvala families have been partners in Sterling and Wilson for 3 generations. This partnership will only grow stronger, as the 4th generations of both families have recently joined the business.
Over the past 5 years, Sterling and Wilson has shown exceptional growth; with operations all over the globe, as well as an expansion in its range of services, the company's turnover has shown an extremely positive growth. From a turnover of INR 1,760 crore in 2012, Sterling and Wilson group crossed a turnover of INR 6,000 crore last year as is likely to exceed INR 10,000 crore in the year ended March 2018. From being a predominantly India focussed company in 2010, Sterling and Wilson now operates across the Middle East, Africa, Australia and Europe. In the current year, the company is expanding to the USA and South America. From being a company that was mainly focussed on doing MEP projects in India, Sterling and Wilson over the past 5 years has set up global operations in manufacture of DG sets, Gas based power plants, Waste to Energy, Turnkey data centers, Transmission and Distribution and Solar EPC. With its recent forays into wind and energy storage, Sterling and Wilson is perfectly poised to play a pivotal role in the global trend of moving away from thermal plants to a future of renewable energy with storage.
Visit us at www.sterlingandwilson.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170619006072/en/
Contact information
MSLGROUP
Bidisha Mukherjee
Senior Account Executive
Mobile:
+91 9619343799
bidisha.mukherjee@mslgroup.com
or
Binay
Joshi
Management Associate
Mobile: +91 8596960780
binay.joshi@mslgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom